Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2020 October;111(5) > Minerva Medica 2020 October;111(5):478-90

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

SPECIAL ARTICLE  ACUTE LEUKEMIAS IN 2020: STATE OF THE ART Freefree

Minerva Medica 2020 October;111(5):478-90

DOI: 10.23736/S0026-4806.20.07031-7

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia

Francesco LANZA 1 , Enrico MAFFINI 1, Francesco SARACENI 2, Evita MASSARI 3, Michela RONDONI 1, Giulia DAGHIA 1, Attilio OLIVIERI 2, Claudio CERCHIONE 4, Giovanni MARTINELLI 5

1 Hematology Unit and Romagna Transplant Network, “Santa Maria delle Croci” Hospital, Ravenna, Italy; 2 Unit of Hematology, University of Ancona, Ancona, Italy; 3 Laboratory Service, AUSL Romagna, Cesena, Italy; 4 Unit of Hematology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì-Cesena, Italy



Patients with acute lymphoblastic leukemia (ALL) are characterized by an unfavorable outcome in the majority of adult cases. Several clinical trials have confirmed the usefulness of a pediatric-type therapy applied to adult patients. Adults present with higher risk features at diagnosis that predispose them to chemotherapy resistance and disease relapse after an initial achievement of complete remission. The recent introduction of novel immune-targeted therapies, including monoclonal antibodies (MoAbs) targeting B cell-associated antigens such as CD19 (blinatumumab) and CD22 (inotuzumab), tyrosine kinase inhibitors targeting BCR-ABL1 tyrosine kinase, bispecific antibodies and chimeric antigen receptor T- cell therapy (CAR-T), circumvent B-ALL cell chemo-refractoriness through novel mechanisms of action, potentially eradicating minimal residual disease (MRD) and enabling more patients to receive allogeneic hematopoietic stem cell transplantation and to achieve a better clinical outcome.


KEY WORDS: Drug therapy; Inotuzumab ozogamicin; Leukemia

top of page